Aromatase inhibitor shows promise for breast cancer patients
14th Dec 2005, 20:12 GMT
Filed under: Breast Cancer, Drug Women with hormone-sensitive early breast cancer are getting benefits from the drug Novartis's Femara. The Swiss drug maker presented data at the 28th annual San Antonio Breast Cancer Symposium in Texas revealing that the aromatase inhibitor showed a benefit in starting therapy up to five years after the end of standard tamoxifen treatment. In a press relaes Novartis claimed, "Postmenopausal women who switched from placebo to Femara experienced a 69-percent reduction in the risk that their breast cancer would return." Read Permalink | Email this | Linking Blogs | Comments
Aromatase inhibitor shows promise for breast cancer patients related news:
- More women will survive breast cancer with Arimidex (anastrozole) than tamoxifen — OnMedica Latest News
- Survival Benefit For Arimidex™ In Early Breast Cancer — Medical News Today RSS/XML Feed
- Low-dose Chemotherapy Plus Antiangiogenesis Drug Has Activity In Advanced Breast Cancer — ScienceDaily Headlines: Health & Medicine
- Breast cancer drugs may slow growth of lung cancer — EurekAlert! - Breaking News
- Radiotherapy boosts survival rate for breast cancer patients: study — The Earth Times Online Newspaper
- Radiation Saves Lives of Breast Cancer Patients, Study Shows; 'Women Shouldn't Fear Radiation Therapy They Should Welcome Its Benefits' Group Says — U.S. Newswire Releases
- 'I just got breast cancer.' — Breast Cancer Chronicles
- Study Boosts Breast Cancer Survival — Sky News UK: Brings you closer to the news across Britain
- Stem cell booster drug may prove a help to cancer patients — The Diabetes Blog
- Fatigue fairly uncommon after breast cancer chemo — RedOrbit News - Health